Current Diabetes Reports

, Volume 6, Issue 5, pp 389–394 | Cite as

Orlistat: Current issues for patients with type 2 diabetes

  • Juliet M. Mancino


Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in patients with type 2 diabetes. There are a number of trials that demonstrate the bene fits of orlistat over placebo for reducing body weight and improving other health parameters. Of some interest are the preliminary explorations of interaction on cytokine levels, where a possible cardiovascular benefit is plausible. Implications of the FDA approval of over-the-counter use and the pharmaceutical development of another lipase inhibitor are also examined.


Metformin Lifestyle Intervention Orlistat Sibutramine Lipase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    WIN Weight-control Information Network: Statistics related to overweight and obesity. http://win.niddk.nih. gov/statistics/index.htm. Accessed March 5, 2006.Google Scholar
  2. 2.
    National Institutes of Health National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The evidence report. NIH Publication #98-4083. Bethesda, MD: National Institutes of Health; 1998.Google Scholar
  3. 3.
    Zhaoping L, Maglione M, Tu W, et al.: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532–546.Google Scholar
  4. 4.
    Sjostrom L, Rissanen A, Andersen T, et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998, 352:160–161.CrossRefGoogle Scholar
  5. 5.
    Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242.PubMedCrossRefGoogle Scholar
  6. 6.
    Hollander P, Elbein S, Hirsch I, et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288–1294.PubMedCrossRefGoogle Scholar
  7. 7.
    Hutton B, Ferguson D: Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004, 80:1461–1468. An excellent review of the trials that establish that orlistat with lifestyle intervention is more effective than lifestyle intervention alone for weight loss.PubMedGoogle Scholar
  8. 8.
    Kelley DE, Kuller LH, McKolanis TM, et al.: Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004, 27:33–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Halpern A, Mancini MC, Suplicy H, et al.: Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003, 5:180–188.PubMedCrossRefGoogle Scholar
  10. 10.
    Didangelos T, Thanopoulou A, Bousboulas S, et al.: The ORLIstat and Cardiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) study. Curr Med Res Opin 2004, 20:1393–1401.PubMedCrossRefGoogle Scholar
  11. 11.
    Guy-Grand B, Drouin P, Eschwege E, et al.: Effects of orlistat on obesity-related diseases: a six-month randomized trial. Diabetes Obes Metab 2004, 6:375–383.PubMedCrossRefGoogle Scholar
  12. 12.
    Lindgarde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245–254.PubMedCrossRefGoogle Scholar
  13. 13.
    Hanefield M, Sachse G: The effects of orlistat on body weight and glycemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002, 4:415–423.CrossRefGoogle Scholar
  14. 14.
    Miles JM, Leiter L, Hollander P, et al.: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002, 25:1123–1128.PubMedCrossRefGoogle Scholar
  15. 15.
    Kelley DE, Bray GA, Pi-Sunyer FX, et al.: Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002, 25:1033–1041.PubMedCrossRefGoogle Scholar
  16. 16.
    Berne C: A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. The Orlistat Swedish Type 2 diabetes Study Group. Diabet Med 2005, 22:612–618.PubMedCrossRefGoogle Scholar
  17. 17.
    Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.PubMedCrossRefGoogle Scholar
  18. 18.
    Heymsfield S, Segal K, Hauptman J: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321–1326.PubMedCrossRefGoogle Scholar
  19. 19.
    Torgerson J, Hauptman J, Boldrin M, et al.: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155–161. This excellent report details the use of orlistat in a prospective randomized diabetes prevention clinical trial.PubMedCrossRefGoogle Scholar
  20. 20.
    Padwal R, Majumdar S, Johnson J, et al.: A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005, 28:736–744.PubMedCrossRefGoogle Scholar
  21. 21.
    Resnick HE, Foster GL, Bardsley J, Ratner RE: American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006, 29:531–537.PubMedCrossRefGoogle Scholar
  22. 22.
    Maetzel A, Ruof J, Covington M, et al.: Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003, 21:501–512.PubMedCrossRefGoogle Scholar
  23. 23.
    Rowe R, Cowx M, Poole C, et al.: The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 2005, 21:1885–1890.PubMedCrossRefGoogle Scholar
  24. 24.
    Lacey LA, Wolf A, O’Shea D, et al.: Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond) 2005, 29:975–982.CrossRefGoogle Scholar
  25. 25.
    Libby P, Ridker P, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143.PubMedCrossRefGoogle Scholar
  26. 26.
    Samuelsson L, Gottsäter A, Lindgärde F: Decreasing levels of tumour necrosis factor and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003, 5:195–201.PubMedCrossRefGoogle Scholar
  27. 27.
    Hsieh CJ, Wang PW, Liu RT, et al.: Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005, 67:78–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Yesilbursa D, Serdar A, Heper Y, et al.: The effect of orlistatinduced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol 2005, 60:265–269.PubMedCrossRefGoogle Scholar
  29. 29.
    Dimitrov D, Bohchelian H, Koeva L: Effect of orlistat on plasma leptin levels and risk factors for the metabolic syndrome. Metabolic Syndrome Related Disorders 2005, 3:122–129.CrossRefGoogle Scholar
  30. 30.
    Moyers S: Medication as adjunct therapy for weight loss: approved and off-label agents in use. J Am Diet Assoc 2005, 105:948–959.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  1. 1.Department of Medicine, Division of Endocrinology & MetabolismUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations